Dollars for Profs
Dig Into University Researchers' Outside Income and Conflicts of Interest
Published Dec. 6, 2019
This database was last updated in December 2019 and should only be used as a historical snapshot. There may be new or amended records not reflected here.
Conflict of Interest
Institutions must file significant disclosures to the National Institutes of Health if they determine financial relationships could affect the design, conduct or reporting of the NIH-funded research. The NIH provided us with their entire financial conflict of interest database, with filings from 2012 through 2019.
Should you be removed from our database? Contact us at [email protected]. Read more below.
Peiman Hematti
University of Wisconsin Madison, Department: Internal Medicine/medicine
Should you be removed from our database? Contact us at [email protected]. Read more below.
Cellular Logistics, Inc.
Equity Interest - Non-publicly traded entity ( e.g., stock, stock option, or other ownership interest)
An outside activity has a nexus with an individual's research activities if the outside activity arises from, relies upon or is related to the academic expertise that qualifies that individual to participate in federally funded research or human subjects research. The Institution has reasonably determined that the significant financial interest could directly and significantly affect the design, conduct, or reporting of the PHS-funded research and so requires management.
Molecular and Cellular Mechanisms of Chronic Myelomonocytic Leukemia (CMML)
PROJECT NARRATIVE Chronic myelomonocytic leukemia (CMML) is a devastating disease that primarily affects the elderly. Oncogenic NRAS mutations are frequently identified in CMML patients. In the prior funded period, we focused on its role in initiation and progression of CMML. In this application, we propose to investigate how the genetic interaction between oncogenic Nras signaling and mutations in epigenetic regulators promotes CMML progression and transformation to AML. Furthermore, we will determine whether effective targeting of oncogenic Ras signaling or simultaneous targeting Ras signaling and aberrant epigenetic landscape could be promising therapeutic strategies against CMML progression, transformation to AML, and/or AML progression in vivo. Because oncogenic NRAS mutations are associated with mutations in epigenetic regulators in multiple myeloid diseases, successful completion of the proposed studies has broad impact on understanding their genetic interaction in hematological malignancies, including but not limiting to CMML.
Filed on March 09, 2017.
Tell us what you know about Peiman Hematti's disclosure
We're still reporting about conflicts of interest. Is there something you'd like to tell us about this disclosure?
Other search results for: “Peiman Hematti”
Name | Institution | Type | Company | Disclosed Value |
---|---|---|---|---|
Peiman Hematti | University of Wisconsin Madison | Conflict of Interest | Cellular Logistics, Inc. | $20,000 - $39,999 |
Peiman Hematti | University of Wisconsin Madison | Conflict of Interest | Cellular Logistics | $0 - $4,999 |
Peiman Hematti | University of Wisconsin Madison | Conflict of Interest | Cellular Logistics, Inc. | $0 - $4,999 |
Notes: When a more specific filing date is not available for an individual financial disclosure or conflict of interest form, we use the year the form was filed. If the year was not disclosed, we report the range of years covered by our public records requests. In a few cases, a start date was provided instead of a filing date. In those cases, we use the start date instead.
Fewer than 10% of records from the University of Florida and fewer than 1% of records from the University of Texas system were removed because they did not contain enough information.
ProPublica obtained additional financial disclosures and conflict of interest forms that we have not yet digitized and added to the database. You can download those disclosures in the ProPublica Data Store.